Table 1.
General characteristic of included randomized controlled trials in the meta‐analysis
| Author | Year of publication | GP/FP | Pathology | Sample size | Outcomes | |
|---|---|---|---|---|---|---|
| GP | FP | |||||
| Bai et al | 2006 | Gem 200 mg·m−25‐Fu 500 mg·m−2d1‐5 + DDP25 mg·m−2d1‐5 | Squamous carcinoma | 93 | 94 | 1‐y survival rate, 3‐y survival rate, remission rate, neutropenia, reduced hemoglobin, reduced platelet, digestive symptoms |
| Cai et al | 2009 | Gem 1000 mg·m−2d1, 8 + DDP25 mg·m−2d1‐45‐Fu 500 mg·m−2d1‐5 + DDP25 mg·m−2d1‐4 | Squamous carcinoma | 29 | 32 | 1‐y survival rate, 3‐y survival rate, remission rate, reduced hemoglobin, reduced platelet, digestive symptoms |
| Hu et al | 2012 | Gem 1000 mg·m−2d1, 8 + DDP25 mg·m−2d1‐45‐Fu 500 mg·m−2d1‐5 + DDP25 mg·m−2d1‐4 | Squamous carcinoma | 33 | 33 | 1‐y survival rate, remission rate, reduced hemoglobin, reduced platelet |
| Jin et al | 2012 | Gem 1000 mg·m−2d1, 8 + DDP25 mg·m−2d1‐35‐Fu 1000 mg·m−2d1‐5 + DDP80 mg·m−2d1‐3 | – | 173 | 176 | 1‐y survival rate, 3‐y survival rate, remission rate, neutropenia, reduced hemoglobin, reduced platelet, digestive symptoms |
| Mo et al | 2010 | Gem 1000 mg·m−2d1, 8 + DDP25 mg·m−2d1‐35‐Fu 500 mg·m−2d1‐5 + DDP25 mg·m−2d1‐3 | Squamous carcinoma | 27 | 29 | Remission rate, reduced hemoglobin, digestive symptoms, mucosal inflammation |
| Yan et al | 2006 | Gem 1250 mg·m−2d1, 8 + DDP25 mg·m−2d15‐Fu 1000 mg·m−2d1‐5 + DDP25 mg·m−2d1 | Squamous carcinoma | 34 | 28 | 1‐y survival rate, 3‐y survival rate, remission rate, neutropenia, reduced hemoglobin, reduced platelet, digestive symptoms |
| Wang et al | 2015 | Gem 1000 mg·m−2d1, 8 + DDP25 mg·m−2d1‐35‐Fu 500 mg·m−2d1‐5 + DDP25 mg·m−2d1‐3 | – | 30 | 16 | Remission rate, mucosal inflammation |
| Yuan et al | 2009 | Gem 1000 mg·m−2d1, 8 + DDP25 mg·m−2d1‐45‐Fu 400 mg·m−2d1‐5 + DDP25 mg·m−2d1‐4 | Squamous carcinoma | 30 | 30 | Remission rate, neutropenia, reduced hemoglobin, reduced platelet, digestive symptoms, mucosal inflammation |
| Zhao et al | 2010 | Gem 1000 mg·m−2d1, 8 + DDP25 mg·m−2d1‐35‐Fu 100 mg·m−2d1‐5 + DDP25 mg·m−2d1‐3 | Squamous carcinoma | 23 | 19 | Remission rate, neutropenia, reduced hemoglobin, reduced platelet, digestive symptoms, mucosal inflammation |
| Zou et al | 2011 | Gem 1000 mg·m−2d1,8 + DDP25 mg·m−2d1‐45‐Fu 75 mg·m−2d1‐5 + DDP75 mg·m−2d1‐5 | Squamous carcinoma | 26 | 28 | 1‐y survival rate, 3‐y survival rate, remission rate, neutropenia, reduced hemoglobin, reduced platelet, digestive symptoms |
| Gu et al | 2012 | Gem 800 mg·m−2d1,8 + DDP20 mg·m−2d1‐45‐Fu 500 mg·m−2d1‐5 + DDP20 mg·m−2d1‐4 | Squamous carcinoma | 80 | 80 | 3‐y survival rate, neutropenia, reduced hemoglobin, reduced platelet, digestive symptoms |
| Zheng et al | 2015 | Gem 1000 mg·m−2d1, 8 + DDP25 mg·m−2d1‐35‐Fu 800 mg·m−2d1‐5 + DDP80 mg·m−2d1‐3 | Squamous carcinoma | 13 | 36 | 3‐y survival rate |
| Zhang et al | 2016 | Gem1 g·m2‐8 cisplatin 80 mg·m2‐15‐Fu 4 g·m2 96 h cisplatin 80 mg·m2‐1 | Squamous carcinoma | 181 | 181 | Anemia, neutropenia, digestive symptoms |